Solid Tumours

In the absence of randomized prospective trials, the EBMT registry remains an important source to survey indications, outcome and clinical risk factors in patients with solid tumours treated by auto- and allo-HCT. At the end of 2022, the EBMT registry included 65,586 HCT for solid tumours in 47,221 patients, with a slight prevalence in adults compared with children (58% vs. 42%). Auto-HCT represented 97% of the total HCT, whereas allo-HCT was used in 3% of the procedures. Multiple transplants were performed in 1/3 of the cases (Table 94.1; Figs. 94.1 and 94.2) compare activity and indications between adults and children.